PRME
Prime Medicine, Inc.
3.00$
-0.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -100.0% | – | – | – | – | – | -100.0% | – | – | – | -97.7% | +6,291.5% | -99.4% | +944.5% | -33.4% | -23.3% | +9.9% | -31.6% | +2.1% | +34.8% | – | |
| – | – | +262.7% | -74.6% | – | – | – | – | +18.2% | +7.9% | +5.9% | +18.2% | -4.8% | -71.5% | +5.5% | +17.0% | +1.3% | +10.2% | -1.0% | +9.6% | +2,260.0% | -95.7% | -1.1% | – | – | |
| – | – | – | – | – | – | – | – | – | – | -351.8% | – | – | – | – | – | – | +944.5% | -33.4% | -151.5% | – | – | -219.3% | – | – | |
| – | +36.8% | +262.7% | +24.7% | +29.9% | +614.7% | -74.1% | +38.5% | +32.2% | +16.0% | +6.3% | +12.0% | +18.4% | +1.2% | -8.9% | +14.0% | -6.3% | -15.5% | +18.9% | +2.0% | +6.3% | -21.1% | -1.7% | -2.1% | – | |
| – | +6.9% | +3.8% | +67.1% | +30.4% | +137.4% | -13.4% | +18.4% | -10.3% | +45.7% | -4.9% | +16.4% | -1.5% | +24.7% | -14.7% | +12.9% | +11.9% | -12.8% | +8.0% | -1.3% | -14.6% | +31.5% | +18.1% | -36.6% | – | |
| – | -38.4% | +3.8% | +393.4% | +52.1% | +476.2% | -66.9% | +32.2% | +20.3% | +22.2% | +3.5% | +13.0% | +13.7% | +32.2% | -30.0% | +16.9% | -2.2% | -14.8% | +16.0% | -2.3% | -78.7% | +341.2% | +0.4% | -10.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -19.5% | -40.3% | -62.3% | -73.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -1,183.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +46,575.0% | -132.9% | – | -312.0% | – | -138.5% | – | – | -187.7% | – | – | -448.4% | – | -76.0% | -200.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -2,764.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -742.8% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.